Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery

NCT04369703 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04369703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04369703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery
Lead sponsor
Mayo Clinic
Phase
Observational
Overall status
Completed
Start date
January 28, 2020
Completion date
April 29, 2022
Enrollment
199 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pituitary tumor, sellar and suprasellar masses